The pathogenic role of the BRCA2 c. 7847C >T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition
Cancer Science · 2023
DOI: 10.1111/cas.15799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Kazuki Yamazawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Substantial numbers of variants of unknown significance (VUSs) have been identified in BRCA1 / 2 through genetic testing, which poses a significant clinical challenge because the contribution of these VUSs to cancer predisposition has not yet been determined. Here, we report 10 Japanese patients from seven families with breast or ovarian cancer harboring the BRCA2 c.7847C>T (p.Ser2616Phe) variant that was interpreted as a VUS. This variant recurs only in families from Japan and has not been reported in the global general population databases. A Japanese patient with Fanconi anemia with compound heterozygous variants c.7847C>T (p.Ser2616Phe) and c.475+1G>A in BRCA2 was reported. In silico predictions and quantitative cosegregation analysis suggest a high probability of pathogenicity. The clinical features of the variant carriers were not specific to, but were consistent with, those of patients with hereditary breast and ovarian cancer. A validated functional assay, called the mixed‐all‐nominated‐in‐one‐BRCA (MANO‐B) method and the accurate BRCA companion diagnostic (ABCD) test, demonstrated the deleterious effects of the variant. Altogether, following the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines, this variant satisfied the “PS3,” “PM2,” “PM3,” and “PP3” criteria. We thus conclude that the BRCA2 c.7847C>T (p.Ser2616Phe) variant is a “likely pathogenic” variant that is specifically observed in the Japanese population, leading to a breast and ovarian cancer predisposition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- Department of Genetic Medicine, Sasaki Foundation, Kyoundo Hospital, Tokyo, Japan.
- Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
- Department of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
- Department of Obstetrics and Gynecology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- Division of Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Kazuki Yamazawa, Hiroyuki Mano, Shinji Kohsaka
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Yamazawa, K., Sugano, K., Tanakaya, K., Inoue, S., Murakami, H., Nakashima, M., Adachi, M., Oki, S., Makabe, T., Yamashita, H., Ueki, A., Sasaoka, A., Nakashoji, A., Kinoshita, T., Matsunaga, T., Arai, M., Nakamura, S., Miyata, H., Ikegami, M., …, & Matsui, A. (2023). The pathogenic role of the BRCA2 c. 7847C >T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition. Cancer Science. https://doi.org/10.1111/cas.15799
Vancouver
Yamazawa K, Sugano K, Tanakaya K, Inoue S, Murakami H, Nakashima M, et al. The pathogenic role of the BRCA2 c. 7847C >T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition. Cancer Science. 2023. doi:10.1111/cas.15799
BibTeX
@article{Yamazawa2023,
author = {Yamazawa, Kazuki and Sugano, Kokichi and Tanakaya, Kohji and Inoue, Satomi and Murakami, Haruka and Nakashima, Moeko and Adachi, Masataka and Oki, Shinya and Makabe, Takeshi and Yamashita, Hiroshi and Ueki, Arisa and Sasaoka, Ayako and Nakashoji, Ayako and Kinoshita, Takayuki and Matsunaga, Tatsuo and Arai, Masami and Nakamura, Seigo and Miyata, Hiroaki and Ikegami, Masachika and Mano, Hiroyuki and Kohsaka, Shinji and Matsui, Akira},
title = {The pathogenic role of the BRCA2 c. 7847C >T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15799}
}
EUVIMED